Analytical Data
-
基因名
HLA-A*11:01&B2M&KRAS WT(VVVGAGGVGK) Tetramer
- Application
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAV53343.1 (G25-T305)&P61769
-
表达区间
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGAGGVGK
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) tetramer is a recombinant protein designed for studying T cell responses in cancer immunology. Human leukocyte antigen (HLA) A*11:01, a major histocompatibility complex (MHC) class I molecule, presents antigens to CD8+ T cells, playing a critical role in the immune response against tumors. The inclusion of β2-microglobulin (B2M) is essential for the stability and proper functioning of the HLA complex. The KRAS gene is frequently mutated in various cancers, and its wild-type (WT) form is significant for understanding T cell recognition and the immune landscape in cancer, particularly in tumors expressing the antigen epitope VVVGAGGVGK. Studying this tetramer can provide insights into the immune mechanisms involved in recognizing and targeting KRAS-expressing tumor cells. The research can enhance our understanding of T cell-mediated immunity and aid in the development of targeted immunotherapies, offering potential therapeutic strategies for cancers associated with KRAS mutations. Additionally, this tetramer can be used in the monitoring of patient responses to cancer vaccines and in evaluating the efficacy of immunotherapies that aim to elicit a robust T cell response against tumor antigens. Overall, the HLA-A*11:01&B2M&KRAS WT tetramer serves as a valuable tool for exploring the dynamics of tumor immunity, paving the way for advancements in cancer treatment approaches.
